The impairment of the Growth Hormone/Insulin-like growth factor 1 (IGF-1) axis in heart failure: A possible target for future therapy

Submitted: June 19, 2018
Accepted: July 30, 2018
Published: September 5, 2018
Abstract Views: 1391
PDF: 956
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


Hormonal abnormalities are quite common in chronic heart failure (CHF). The most studied hormonal axis in CHF is the impairment of Growth Hormone (GH)/Insulin Growth Factor-1(IGF-1), which in turn is defined either by a blunted response to GH stimulation test or low serum IGF-1 values.  Several independent groups reported that the presence of an abnormal GH/IGF-1 status in CHF is associated with a more severe disease, impaired functional capacity and reduced Survival rates. After the first encouraging results, double -blind controlled trials showed a neutral effect of the GH administration in patients. However, further studies reported positive results, when a GH-therapy is implemented only in those patients presenting a GH deficiency (replacement therapy).



PlumX Metrics


Download data is not yet available.


How to Cite

Piccioli, Lucrezia, Michele Arcopinto, Andrea Salzano, Roberta D’Assante, Alessandra Schiavo, Francesca M. Stagnaro, Anna Lombardi, Veronica Panicara, Pietro Valente, Giuseppe Vitale, Filippo M. Sarullo, Francesco Giallauria, and Alberto M. Marra. 2018. “The Impairment of the Growth Hormone/Insulin-Like Growth Factor 1 (IGF-1) Axis in Heart Failure: A Possible Target for Future Therapy”. Monaldi Archives for Chest Disease 88 (3).